KR20240095294A - 실로시빈 유사체의 제형 및 사용 방법 - Google Patents

실로시빈 유사체의 제형 및 사용 방법 Download PDF

Info

Publication number
KR20240095294A
KR20240095294A KR1020247017594A KR20247017594A KR20240095294A KR 20240095294 A KR20240095294 A KR 20240095294A KR 1020247017594 A KR1020247017594 A KR 1020247017594A KR 20247017594 A KR20247017594 A KR 20247017594A KR 20240095294 A KR20240095294 A KR 20240095294A
Authority
KR
South Korea
Prior art keywords
salt
pharmaceutical composition
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017594A
Other languages
English (en)
Korean (ko)
Inventor
알렉스 니보로즈킨
마이클 팔프리먼
프래딥 엠. 파싸어
케네스 엘. 애버리
모함메드 아이. 슈쿠
제임스 헤 후앙
마이클 이. 모르간
조안 엠. 크라코스키
Original Assignee
사이빈 아이알엘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/056991 external-priority patent/WO2022195011A1/en
Application filed by 사이빈 아이알엘 리미티드 filed Critical 사이빈 아이알엘 리미티드
Publication of KR20240095294A publication Critical patent/KR20240095294A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247017594A 2021-11-05 2022-09-20 실로시빈 유사체의 제형 및 사용 방법 Pending KR20240095294A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163276117P 2021-11-05 2021-11-05
US63/276,117 2021-11-05
EPPCT/EP2022/056991 2022-03-17
PCT/EP2022/056991 WO2022195011A1 (en) 2021-03-18 2022-03-17 Psilocybin analogs, salts, compositions, and methods of use
PCT/EP2022/076073 WO2023078604A1 (en) 2021-11-05 2022-09-20 Formulations of psilocybin analogs and methods of use

Publications (1)

Publication Number Publication Date
KR20240095294A true KR20240095294A (ko) 2024-06-25

Family

ID=83558221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017594A Pending KR20240095294A (ko) 2021-11-05 2022-09-20 실로시빈 유사체의 제형 및 사용 방법

Country Status (9)

Country Link
US (1) US20250213527A1 (https=)
EP (1) EP4426675A1 (https=)
JP (1) JP2024540282A (https=)
KR (1) KR20240095294A (https=)
CN (1) CN117177959A (https=)
AU (1) AU2022381220B2 (https=)
CA (1) CA3236624A1 (https=)
IL (1) IL312175A (https=)
WO (1) WO2023078604A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス, インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
CA3247344A1 (en) * 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
US12049447B2 (en) 2022-06-30 2024-07-30 Zylorion Health Inc. Crystalline forms of compositions comprising psilocin and psilocybin
AU2023343417B2 (en) * 2022-09-12 2026-02-19 Tryp Therapeutics, Inc Psilocin crystalline forms
WO2024180030A1 (en) 2023-02-27 2024-09-06 Cybin Irl Limited Methods of treating depressive disorders with a psilocybin analog
WO2025019800A1 (en) * 2023-07-19 2025-01-23 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
US12280068B1 (en) 2023-11-09 2025-04-22 Zylorion Health Inc. Uses of a co-crystal of psilocybin and psilocin
US20250302075A1 (en) * 2024-04-01 2025-10-02 Tsi Group Co., Ltd. Compositions and methods of preparation of a clear, effervescent delivery form for nutritional ingredients
US20260021070A1 (en) * 2024-07-19 2026-01-22 Compass Pathfinder Limited Subcutaneous formulations comprising psilocybin derivatives
CN119610304A (zh) * 2024-12-10 2025-03-14 澳创新耐火材料(中山)有限公司 一种低值植物纤维材料重组防火门芯及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2022195011A1 (en) * 2021-03-18 2022-09-22 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use

Also Published As

Publication number Publication date
IL312175A (en) 2024-06-01
AU2022381220B2 (en) 2026-03-05
AU2022381220A1 (en) 2024-05-02
EP4426675A1 (en) 2024-09-11
CN117177959A (zh) 2023-12-05
US20250213527A1 (en) 2025-07-03
WO2023078604A1 (en) 2023-05-11
JP2024540282A (ja) 2024-10-31
CA3236624A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
US20250213527A1 (en) Formulations of psilocybin analogs and methods of use
AU2022342266B2 (en) Combination drug therapies
KR20240009433A (ko) 실로시빈의 제형
WO2022195011A1 (en) Psilocybin analogs, salts, compositions, and methods of use
JP2025505745A (ja) フェネチルアミン誘導体、組成物、及び使用方法
EP4499087A1 (en) Combination of nitrous oxide and 5-ht2a receptor agonists
US20250236589A1 (en) Therapeutic phenethylamine compositions and methods of use
AU2023207801B2 (en) Tryptamine compositions and methods
KR20250053871A (ko) 트립타민 화합물, 조성물, 및 사용 방법
WO2024089226A1 (en) Phenethylamine compounds, compositions, and methods of use
CN118234708A (zh) 裸头草碱类似物的调配物和使用方法
US20240174607A1 (en) Psilocybin analogs, salts, compositions, and methods of use
JP2026513655A (ja) フェネチルアミン化合物、組成物、及び使用方法
CN118632835A (zh) 色胺组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000